CompletedPhase 2NCT00847639

Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma

Studying Multiple myeloma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Center for International Blood and Marrow Transplant Research
Principal Investigator: Melissa Alsina, MD, PA-C
H. Lee Moffitt Cancer Center
Intervention: lenalidomide(drug)
Enrollment: 30 target
Eligibility: 18-70 years · All sexes
Timeline: 2009 – 2014

Study locations (8)

City of Hope National Medical Center, Duarte, California, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
University of Pennsylvania Hospital Center, Philadelphia, Pennsylvania, United States
The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Collaborators

National Marrow Donor Program · Celgene Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00847639 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma →

← Back to all trials